The Longevity Health Holdings, Inc. (XAGE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, transaction documents, and listing-related notices. These filings offer detailed information on Longevity’s focus on human longevity and healthy aging through regenerative bio-aesthetics, diagnostics, and nutrition, as well as its corporate and capital markets activities.
Among the key documents are Form 8-K current reports describing material events, such as merger agreements and amendments with 20/20 BioLabs, Inc. and True Health Inc. (THPlasma), and the subsequent termination of the merger agreement with True Health after the transaction was not consummated by the contractual outside date. These reports outline transaction structures, share consideration formulas, and the conditions required for closing.
Investors can also review a Form 25 filed by Nasdaq Stock Market LLC, which serves as a notification of removal of Longevity Health Holdings, Inc.’s common stock and warrants from listing and registration under Section 12(b) of the Securities Exchange Act of 1934 on the Nasdaq Stock Market. This filing documents the delisting process from Nasdaq.
Through Stock Titan, users can follow Longevity’s 10-K annual reports, 10-Q quarterly reports, and additional 8-Ks as they are filed with the U.S. Securities and Exchange Commission. AI-powered summaries help explain the significance of lengthy filings, highlight key risk factor updates, and surface important details in merger agreements, listing decisions, and financing disclosures. The page also makes it easier to monitor insider and executive-related filings, where available, and to understand how corporate actions affect the company’s structure and shareholders.
Longevity Health Holdings (XAGE) amended its merger agreement with True Health. The revision sets how stock consideration will be calculated. The Merger Shares will equal $59,000,000 divided by the lesser of the “Parent Market Price” and $3.00. The Earnout Shares will equal $20,000,000 divided by the lesser of the Parent Market Price and $3.00. Parent Market Price is defined as the volume average weighted closing sale price over the 15 consecutive full trading days immediately before the merger’s effective time.
As outlined previously, upon closing, True Health would become a wholly owned subsidiary and the company would acquire specified FDA authorizations from Truehealth Management Group LLC. The filing reiterates customary risks, including required regulatory approvals, satisfaction of closing conditions, potential Nasdaq listing considerations for the combined company, integration execution, and market price variability relative to the Parent Market Price.